LeanGLP

Mounjaro (tirzepatide) titration schedule — straight from the FDA label

By The LeanGLP Team · Label information verified 2026-08-05

This is label information, not a recommendation. The table below reproduces the escalation schedule from the official U.S. prescribing information so you can understand what a typical plan looks like. Your prescriber sets your actual doses and timing — follow their instructions, not this page. This site never computes patient-specific doses.

Mounjaro is tirzepatide, a once-weekly subcutaneous injection from Eli Lilly. Type 2 diabetes (adults and, per the 2025 label update, pediatric patients 10+) — per the prescribing information. Same molecule as Zepbound, different approved indication.

Dose-escalation schedule (per the prescribing information)

PeriodDoseLabel note
Weeks 1-42.5 mg once weeklyLabel: 2.5 mg is for treatment initiation and is not intended for glycemic control.
Week 5 onward5 mg once weekly
If more glycemic control is needed (≥4 weeks per step)Increase in 2.5 mg increments (7.5 → 10 → 12.5 → 15 mg)

Maintenance dosing

Recommended maintenance dosages: 5 mg, 10 mg, or 15 mg once weekly. Maximum: 15 mg once weekly in adults (10 mg in pediatric patients).

Plain-language notes

  • Mounjaro and Zepbound are both tirzepatide; the escalation ladder is the same shape, but indications and some maximums differ by label.

Why the slow ramp exists

Every GLP-1 label escalates gradually for the same stated reason: reducing gastrointestinal side effects while the body adapts. For nutrition planning, the escalation window is when appetite suppression tends to hit hardest — which is exactly when protein intake usually craters. That's the problem our GLP-1 protein calculator and week-one meal plan are built for.

Sources

Schedules can change when the FDA approves label revisions — the links above always point at the current official documents. If you spot a discrepancy, tell us and we'll correct it fast.

Frequently asked questions

Is Mounjaro the same as Zepbound?

Both contain tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. The titration ladders look similar, but each label's indication and pediatric provisions differ.